NasdaqGS:ALNYBiotechs
Alnylam Raises 2025 Revenue Guidance as Losses Widen Might Change The Case For Investing In ALNY
Alnylam Pharmaceuticals raised its full-year 2025 net product revenue guidance to between US$2.65 billion and US$2.8 billion following the release of its second-quarter results, which showed revenue growth to US$773.69 million and an increased net loss to US$66.28 million for the quarter ended June 30, 2025.
While overall revenues saw substantial gains year-over-year, the company also reported a larger net loss and higher basic loss per share from continuing operations compared to the prior...